Opendata, web and dolomites

CB-103

First effective targeted therapy for T-cell acute lymphoblastic leukemia (T-ALL) and other NOTCH pathway driven cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CB-103 project word cloud

Explore the words cloud of the CB-103 project. It provides you a very rough idea of what is the project "CB-103" about.

ineffective    marrow    cancerous    chemotherapy    dependent    strategy    healthy    complete    additionally    cb    indicate    inhibiting    scalable    compound    103    median    acute    trials    model    killing    people    limiting    answer    stage    molecule    25    tumorigenesis    drugs    conventional    stopping    blood    roots    improvement    aggressive    prolongs    standard    adverse    aged    too    therapeutic    cell    blocks    accounts    collaborations    chain    off    small    oncogenic    issue    14    notch    business    drug    signaling    children    index    breast    roles    dose    verifying    clinical    bone    toxicity    leukemia    forms    relative    treatment    significantly    ones    cellestia    colorectal    afflicted    benefit    drive    rates    250    dlt    transcription    reduce    activated    75    supply    care    total    survival    lung    lymphoblastic    stem    downstream    planning    cancer    commercialization    thanks    found    cure    play    progression    toxicological    expansion    establishing    cells       efficiency    tumor    cancers    discriminate   

Project "CB-103" data sheet

The following table provides information about the project.

Coordinator
CELLESTIA BIOTECH AG 

Organization address
address: HOCHBERGERSTRASSE 60 C
city: Basel
postcode: CH 4057
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.cellestia.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLESTIA BIOTECH AG CH (Basel) coordinator 50˙000.00

Map

 Project objective

T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive NOTCH-dependent cancer that affects the blood and bone marrow especially in children aged 0-14 years, and currently has no effective cure. T-ALL accounts for about 25% of the total cases of Lymphoblastic Leukemia (ALL); additionally, an estimated 250,000 people are afflicted by NOTCH-dependent cancers every year. Chemotherapy, the standard-of-care treatment for T-ALL, can reduce tumor growth, but it is ineffective at killing the cancer stem cells that drive tumor progression. Moreover, it can lead to adverse toxicological effects as a result of off-target toxicity, as the drug cannot discriminate between healthy and cancerous cells. Small molecule drugs help to solve this issue thanks to their high efficiency in targeting tumor cells. Cellestia may have found the answer. Its novel approach targets a tumor development pathway, the NOTCH, which play crucial oncogenic roles in tumorigenesis, tumor expansion and survival. By inhibiting the NOTCH signaling in its most downstream part, Cellestia’s small molecule compound, CB-103, blocks the problem at the roots (i.e. specifically at the level of the NOTCH transcription complex) stopping cancer cells growth and survival. Pre-clinical results show CB-103 to have a high therapeutic index relative to conventional cancer drugs. Most importantly, it significantly prolongs survival rates (median improvement of 75%) with no adverse side effects or dose-limiting toxicity (DLT). Results indicate it may have benefit for other cancers too – any in which NOTCH pathway is highly activated, including forms of leukemia and other cancers such as lung, breast and colorectal. The Phase 1 project will be focused on establishing a complete and scalable supply chain, verifying the business model and commercialization strategy, planning new collaborations and partnerships, including the ones to implement the next clinical trials stage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CB-103" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CB-103" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More